Less than Nihilism

Chapter 2 by Luca Di Blasi (...) gives us an insight into the history of nihilism, specifically by exposing a continuity (or else a cycle or repetition) between the earliest debates on the subject in the turn of the nineteenth century and latest ones in the turn of the twenty-first Di Blasi emphasizes the fact that the struggle between philosophy and religion, reason and faith, was a pertinent motif in Jacobi’s critique of Fichte’s philosophy and in Hegel’s response to this critique. A similar problematic, and similar dynamic, recurs two centuries later, where debates around the concept of nihilism among thinkers like Vattimo, Derrida, Habermas, and Žižek again revolve around the relation between religion, science, secularism, and “post-secularism.” Beginning with Hegel, Di Blasi’s chapter ends with a focus on Žižek as a “neo-Hegelian” showing how, in attacking his contemporaries, Žižek mirrors and revives Hegel’s approach in his critique of Jacobi and Fichte. Suggestively, Žižek informs us that now “the circle is closed” and that “to be a Hegelian today does not mean to assume the superfluous burden of some metaphysical past, but to regain the ability to begin from the beginning...”

[Molecular targets in colon cancer]

Colorectal cancer is the second leading cause of cancer death in Switzerland. The nihilism that dominated the treatment of these patients for decades has been replaced by a measure of enthusiasm, given recent therapeutic advances. New anticancer drugs such as irinotecan and oxaliplatin have changed the standard chemotherapy treatment of metastatic colorectal cancer. However, the real hype has come from molecular targeted therapy. Identification of cellular processes characteristic of colon cancer has permitted therapeutic targeting with favorable therapeutic index. Inhibition of the epidermal growth factor receptor in the clinic has provided proof of principle that interruption of signal transduction cascades in patients has therapeutic potential. Angiogenesis, especially the vascular endothelial growth factor pathway, has been proven to be another highly successful molecular target. In this article, we will review molecular targets, which are under active clinical investigation in colon cancer.